BARD1 and cancer: CA125 showed higher sensitivity than the BARD1 261-sample-fitted model for OC with or without BRCA1/2 or BARD1 mutations, presumably this reflects that those sub-groups contained more late-stage ovarian cancers, which are better detected by CA125 than early-stage cancers.